"There is something intrinsically sacrificial about participating in biomedical research. Research exposes participants to some risks and often offer little no individual benefits. In some rare and extreme cases, research participants make the ultimate sacrifice: they die as a result of the intervention being tested. When this happens, there is a strong intuition that the participant's family should receive compensation for their loss. The intuition is also embedded in influential ethics guidance that researchers and their funders are supposed to adhere to: those conducting clinical trials are required to have insurance to cover such eventualities."-Global bioethics bloghttp://globalbioethics.blogspot.com/2011/06/doing-what-is-right-when-result-of.html"Clinical trials claimed 25 lives in 2010, only 5 paid compensation""NEW DELHI: Rs 3 lakh – that's the price a pharmaceutical company has paid to the family of a person who died in their clinical trial. Others weren't even this lucky.According to the Drug Controller General of India's (DCGI) records, 25 people died in clinical trials carried out by nine pharmaceutical companies in 2010. Families of five of these victims received "compensation for trial related death" — the amount ranging from Rs 1.5 lakh to Rs 3 lakh."-The Times of Indiahttp://articles.timesofindia.indiatimes.com/2011-06-06/india/29624892_1_clinical-trials-drug-controller-general-dcgi
From 2004:
"Indian Guinea Pigs for Sale: Outsourcing Clinical Trials"
"India has "40 million asthmatic patients, about 34 million diabetic patients, 8-10 million people HIV positive, 8 million epileptic patients, 3 million cancer patients" among other categories, says the company's website. Apparently this is Igate International's 'raw stock'.
"I believe there has been a 10-fold increase in research in the last five years," says Mumbai-based endocrinologist Shashank Joshi. "There are many more contract research organizations and trial centers." According to the website www.biospectrumindia.com, the contract research business in India doubled last year, from Rs 135 crore (about US $ 30 million) to Rs 275 crore (about US $ 60 million). Pharmabiz.com estimates that current outsourced clinical trial activity in India at around Rs 3.5 billion (about US $ 75 million), going up to Rs13.2 billion ((about US $ 281 million) by 2010 - perhaps Rs 44 billion (about US $ 950 million)if regulatory hurdles are "streamlined"."
" According to the official figures, more than 1,500 Indians have died in the course of clinical trials since 2008 — 670 last year alone. And even though few of those deaths were reported to be treatment-related, there is no independent audit system to investigate the fatalities that occur during clinical trials.
Comments
"Indian Guinea Pigs for Sale: Outsourcing Clinical Trials"
"India has "40 million asthmatic patients, about 34 million diabetic patients, 8-10 million people HIV positive, 8 million epileptic patients, 3 million cancer patients" among other categories, says the company's website. Apparently this is Igate International's 'raw stock'.
"I believe there has been a 10-fold increase in research in the last five years," says Mumbai-based endocrinologist Shashank Joshi. "There are many more contract research organizations and trial centers." According to the website www.biospectrumindia.com, the contract research business in India doubled last year, from Rs 135 crore (about US $ 30 million) to Rs 275 crore (about US $ 60 million). Pharmabiz.com estimates that current outsourced clinical trial activity in India at around Rs 3.5 billion (about US $ 75 million), going up to Rs13.2 billion ((about US $ 281 million) by 2010 - perhaps Rs 44 billion (about US $ 950 million)if regulatory hurdles are "streamlined"."
Source-India Resource Center:
http://www.indiaresource.org/issues/globalization/2004/indianguinea...
" According to the official figures, more than 1,500 Indians have died in the course of clinical trials since 2008 — 670 last year alone. And even though few of those deaths were reported to be treatment-related, there is no independent audit system to investigate the fatalities that occur during clinical trials.
Some see the booming industry as a ticking bomb"
source:
http://www.globalpost.com/dispatch/news/regions/asia-pacific/india/...